A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
AstraZeneca
Tesaro, Inc.
NuCana plc
Eli Lilly and Company
GlaxoSmithKline
OncoResponse, Inc.
Case Comprehensive Cancer Center